Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc.

SNOA

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$1.34

$0.00 · 0.00%

Aug 21, 4:00 PM ET

SNOA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

31

Weakening

Sentiment

53

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Amy Trombly
Listed since
Jan 25, 2007
Employees
10

Market position

Day range

Current $1.34

52-week range

Current $1.34

Open
$1.3201
Previous close
$1.34
Volume
66.58K
0.3× average
Average volume
224.69K
Average daily volume
Market cap
2.26M USD
Beta
1.29
Market reference 1
50-day average
$1.2118
+10.58% above average
200-day average
$2.2659
-40.86% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-1.1×
P/B (TTM)
0.78×
P/S (TTM)
0.1×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
38.91%
Operating margin
-6.41%
Net margin
-10.33%

Financial health

Debt / equity
0.11×
Altman Z-score
-13.83
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends47%13%-21%-55%Gross margin, FY2022: 31.62%Gross margin, FY2023: 33.73%Gross margin, FY2024: 37.26%Gross margin, FY2025: 38.25%Gross margin, FY2026: 37.97%Operating margin, FY2022: -46.62%Operating margin, FY2023: -34.43%Operating margin, FY2024: -36.91%Operating margin, FY2025: -25.97%Operating margin, FY2026: -12.60%Net margin, FY2022: -40.28%Net margin, FY2023: -38.81%Net margin, FY2024: -37.97%Net margin, FY2025: -24.20%Net margin, FY2026: -16.26%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 31.62%. Gross margin FY2023 33.73%. Gross margin FY2024 37.26%. Gross margin FY2025 38.25%. Gross margin FY2026 37.97%. Operating margin FY2022 -46.62%. Operating margin FY2023 -34.43%. Operating margin FY2024 -36.91%. Operating margin FY2025 -25.97%. Operating margin FY2026 -12.60%. Net margin FY2022 -40.28%. Net margin FY2023 -38.81%. Net margin FY2024 -37.97%. Net margin FY2025 -24.20%. Net margin FY2026 -16.26%.

Income trends

Revenue

19.53M USD+36.68%

Operating income

−2.46M USD+33.67%

Net income

−3.18M USD+8.16%
Income trends across reported periods22.07M USD11.9M USD1.74M USD−8.43M USDRevenue, FY2022: 12.63M USDRevenue, FY2023: 13.27M USDRevenue, FY2024: 12.74M USDRevenue, FY2025: 14.29M USDRevenue, FY2026: 19.53M USDOperating income, FY2022: −5.89M USDOperating income, FY2023: −4.57M USDOperating income, FY2024: −4.7M USDOperating income, FY2025: −3.71M USDOperating income, FY2026: −2.46M USDNet income, FY2022: −5.09M USDNet income, FY2023: −5.15M USDNet income, FY2024: −4.84M USDNet income, FY2025: −3.46M USDNet income, FY2026: −3.18M USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 12.63M USD. Revenue FY2023 13.27M USD. Revenue FY2024 12.74M USD. Revenue FY2025 14.29M USD. Revenue FY2026 19.53M USD. Operating income FY2022 −5.89M USD. Operating income FY2023 −4.57M USD. Operating income FY2024 −4.7M USD. Operating income FY2025 −3.71M USD. Operating income FY2026 −2.46M USD. Net income FY2022 −5.09M USD. Net income FY2023 −5.15M USD. Net income FY2024 −4.84M USD. Net income FY2025 −3.46M USD. Net income FY2026 −3.18M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue19.53M USD14.29M USD12.74M USD13.27M USD12.63M USD
Cost of goods sold12.11M USD8.82M USD7.99M USD8.8M USD8.64M USD
Gross profit7.42M USD5.47M USD4.75M USD4.48M USD3.99M USD
Research and development2.27M USD1.81M USD1.87M USD207K USD125K USD
Selling, general, and administrative7.61M USD7.36M USD7.58M USD8.84M USD9.76M USD
Operating expenses9.88M USD9.18M USD9.45M USD9.05M USD9.88M USD
Interest income16K USD
Interest expense10K USD
Depreciation and amortization139K USD138K USD176K USD125K USD186K USD
Operating income−2.46M USD−3.71M USD−4.7M USD−4.57M USD−5.89M USD
Net income−3.18M USD−3.46M USD−4.84M USD−5.15M USD−5.09M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-231.61%
11 comparable reports
Latest EPS result
0.02
Estimate -0.3 · Beat by 106.67%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.09-0.23-0.55-0.87Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual -0.59, estimate -0.8, surprise +26.25%, Beat. Q2 2025, reported Jun 17, 2025: actual -0.15, estimate -0.73, surprise +79.45%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.76, estimate -0.51, surprise -49.02%, Miss. Q4 2025, reported Nov 6, 2025: actual -0.32, estimate -0.31, surprise -3.23%, Miss. Q1 2026, reported Feb 4, 2026: actual -0.48, estimate -0.29, surprise -65.52%, Miss. Q2 2026, reported Jun 16, 2026: actual -0.33, estimate -0.24, surprise -37.50%, Miss. Q3 2026, reported Aug 6, 2026: actual 0.02, estimate -0.3, surprise +106.67%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate -0.1, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates6.66M5.54M4.43M3.31MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 3.56M USD, estimate 4.44M USD, surprise -19.73%, Miss. Q2 2025, reported Jun 17, 2025: actual 3.75M USD, estimate 4.44M USD, surprise -15.44%, Miss. Q3 2025, reported Aug 7, 2025: actual 4.02M USD, estimate 4.05M USD, surprise -0.86%, Miss. Q4 2025, reported Nov 6, 2025: actual 5.6M USD, estimate 4.26M USD, surprise +31.55%, Beat. Q1 2026, reported Feb 4, 2026: actual 4.35M USD, estimate 5.47M USD, surprise -20.55%, Miss. Q2 2026, reported Jun 16, 2026: actual 5.56M USD, estimate 5.57M USD, surprise -0.08%, Miss. Q3 2026, reported Aug 6, 2026: actual 6.41M USD, estimate 4.99M USD, surprise +28.38%, Beat. Q4 2026, reported Nov 16, 2026: actual —, estimate 5.29M USD, surprise —, Comparison unavailable.

SNOA news

Corporate actions

Corporate action history

Stock split

Effective Aug 30, 2024

1:20

Stock split

Effective Jun 20, 2019

1:9

Stock split

Effective Jun 27, 2016

1:5

Stock split

Effective Apr 1, 2013

1:7

SNOA peers

ETFs holding SNOA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SNOA

research.disclaimer